 |
|
Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H.
Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol.
2009 Sep;44(9):579-85.
PubMed Abstract
|
|
|
|
|
|
| |
Submit a Comment on this Paper |
|
|
|
|
| |
 |
|
| |
REAGENTS/MATERIAL:
All measurements of CSF Aβ42, CSF t-tau and P-tau181 in CSF
were performed in Munich, Germany (biological PI centre). These
parameters were measured in duplicates with commercially available
enzyme-linked immunosorbent assays (ELISAs)
(Innotest βamyloid1-42 (Innogenetics, Zwjindrecht, Belgium),
Innotest hTAU-Ag (Innogenetics),
Innotest PHOSPHO-TAU (181P) (Innogenetics)
Art. No. K-1080, Art No. K-1032, and Art No. K-1120).
Levels of CSF P-tau231 in CSF were
measured using a sandwich ELISA developed by Applied NeuroSolutions, Inc. (Vernon Hills, IL).
Quantification of β-amyloid isoforms in plasma was performed
in the biological PI centre in Gothenburg, Sweden, using the high
sensitivity INNOTEST Aβ1-42 ELISA (Innogenetics, Ghent, Belgium), as previously described.
β-amyloid 40 levels were determined using the
hAmyloid β40 ELISA Highly Sensitive kit (The Genetics Company, Schlieren, Switzerland).
This assay employs antibody W02 (epitope 5–8 in the Aβ sequence) for capture and the Aβ40 end-specific antibody G2-10 for detection
|
|
|
|
Home
